BMS-906024

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

CancerLymphoblastic Leukemia, Acute T-cellPrecursor T-Cell Lymphoblastic Lymphoma

Phase 1

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

CompletedNCT01292655

Bristol-Myers SquibbCancer

Start: 2011-03-03End: 2017-06-22Updated: 2020-01-27

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

CompletedNCT01363817

Bristol-Myers SquibbLymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma

Start: 2011-09-28End: 2018-02-07Updated: 2019-07-30

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

CompletedNCT01653470

Bristol-Myers SquibbCancer

Start: 2012-10-12End: 2017-05-08Updated: 2020-01-28

Related Papers

Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL

Blood2019-11-13

A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2018-05-2021 citations